Catalent, a company which provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, agreed to acquire US manufacturing facility of Erytech, a biopharmaceutical company, for $44.5m. “In Catalent we have found a great partner for the manufacturing of our innovative red blood cell derived products, and we believe that this strategic partnership will meet our long-term manufacturing needs in the United States. As we are turning this important page for ERYTECH, I wish to thank our entire Princeton team very much for their talent and dedication in building and developing our flagship facility since its inception in 2018. ERYTECH will now further focus capital resources on the development of potentially transformative therapeutics for serious diseases. We are also continuing to evaluate further strategic options for the company, including additional partnerships and addition of complementary assets, through which we can leverage our ERYCAPS® platform and our development and manufacturing capabilities,” Gil Beyen, ERYTECH Chief Executive Officer.